SCHEMBL565865

SCHEMBL565865

N#Cc1cnccc1N1CCCC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 9/20 0.55
ROCK1 Q13464 9/20 0.55
CDC42BPB Q9Y5S2 9/20 0.55
CDC42BPA Q5VT25 3/20 0.55
AR P10275 1/20 0.49
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
CHKA P35790 1/20 0.44
GRM1 Q13255 1/20 0.43
PARP1 P09874 1/20 0.42
CHRM1 P11229 1/20 0.42
CNR2 P34972 1/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30751784 1.00 ROCK2 (0.55) ROCK2ROCK1CDC42BPBCDC42BPAAR
SCHEMBL19095257 0.84 ROCK2 (0.58) ROCK2ROCK1CDC42BPBCDC42BPAALDH1A1
SCHEMBL3345307 0.84 ROCK2 (0.59) ROCK2ROCK1CDC42BPBCDC42BPAALDH1A1
SCHEMBL30510121 0.82 GSK3B (0.47) ROCK2ROCK1CDC42BPBCDC42BPAGRM1
SCHEMBL4871243 0.80 AR (0.65) ROCK2ROCK1CDC42BPBCDC42BPAAR
SCHEMBL4876412 0.80 AR (0.65) ROCK2ROCK1CDC42BPBCDC42BPAAR
SCHEMBL2490932 0.78 CDC42BPB (0.42) ROCK2ROCK1CDC42BPBCDC42BPAGRM1
SCHEMBL29579334 0.78 CDC42BPB (0.40) ROCK2ROCK1CDC42BPBCDC42BPAGRM1
SCHEMBL12836051 0.77 ROCK2 (0.48) ROCK2ROCK1CDC42BPBCDC42BPAGRM1
SCHEMBL1514504 0.77 ROCK2 (0.48) ROCK2ROCK1CDC42BPBCDC42BPAGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3206691-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE Sunshine Lake Pharma Co., Ltd. (CN) 2017-08-23 EP disclosed
US-9499570-B2 Boron containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
WO-2016060963-A1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-04-21 WO disclosed
US-20150376210-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, LLC 2015-12-31 US disclosed
EP-2958910-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS Domainex Limited (GB) 2015-12-30 EP disclosed
US-9145429-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2015-09-29 US disclosed
WO-2014128486-A1 PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS DOMAINEX LIMITED (GB) 2014-08-28 WO disclosed
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2014-07-17 US disclosed
US-8716478-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2014-05-06 US disclosed
US-20120035132-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200198-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 ROCK2 2013/4885ROCK1 2703/4885CDC42BPB 421/4885
US-20120035132-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 ROCK2 2013/4885ROCK1 2703/4885CDC42BPB 421/4885
US-20150376210-A1 BORON-CONTAINING SMALL MOLECULES BTD, BCL6B, BBOX1 ROCK2 2013/4885ROCK1 2703/4885CDC42BPB 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.